SK Bioscience (photo = SK Bioscience homepage)

 

[Alpha Biz= Reporter Kim Minyoung] On the 27th, SK Bioscience announced that it will acquire IDT Biologika GmbH, a German company specializing in vaccine and biological product contract manufacturing (CMO).

IDT Biologika is a leading CMO company in Germany, with experience in handling COVID-19 vaccine contracts for J&J, Janssen, and AstraZeneca. Additionally, the company has a diverse track record, including CMO contracts with domestic botulinum toxin companies.

SK Bioscience has decided to acquire a 60.6% stake in the company for 318.6 billion KRW. With this acquisition, SK Bioscience aims to enhance its corporate value.

 

 

[ⓒ AlphaBIZ. 무단전재-재배포 금지]